Lyka Labs (BOM:500259) Total Liabilities: ₹837 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:500259 Lyka Labs Ltd BOM:500259
51 GF Score
Price ₹63.57
GF Value ₹127.51
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Lyka Labs Total Liabilities?

Lyka Labs BOM:500259 +0.70% 51 Total Liabilities is ₹837 Mil as of Mar. 2026. GuruFocus rates BOM:500259 with a GF Score™ of 51/100 and a GF Value™ of ₹127.51 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Lyka Labs's Total Liabilities for the quarter that ended in Mar. 2026 was ₹837 Mil.

Lyka Labs's quarterly Total Liabilities declined from Sep. 2025 (₹664.32 Mil) to Dec. 2025 (₹0.00 Mil) but then increased from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹837.05 Mil).

Lyka Labs's annual Total Liabilities declined from Mar. 2024 (₹885.90 Mil) to Mar. 2025 (₹726.24 Mil) but then increased from Mar. 2025 (₹726.24 Mil) to Mar. 2026 (₹837.05 Mil).

Lyka Labs Total Liabilities Historical Data

* Premium members only.

The historical data trend for Lyka Labs's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyka Labs Total Liabilities Chart

Lyka Labs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,721.23 1,058.52 885.90 726.24 837.05

Lyka Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 726.24 0.00 664.32 0.00 837.05
BOM:500259
51GF Score
Lyka Labs Ltd BOM:500259
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyka Labs Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Lyka Labs's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=538.992+(229.893+68.165
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=837

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=1745.364-908.314
=837

Lyka Labs's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=538.992+(229.893+68.165
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=837

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=1745.364-908.314
=837

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of ₹837 Mil mean?
Lyka Labs (BOM:500259) has a Total Liabilities of ₹837 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lyka Labs and its competitors.
Is Lyka Labs' Total Liabilities too high?
Lyka Labs' current Total Liabilities is ₹837 Mil. Overall, Lyka Labs has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lyka Labs' Total Liabilities compare to VRTX and REGN?
Lyka Labs' Total Liabilities of ₹837 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Lyka Labs and its competitors. Lyka Labs's current Total Liabilities is ₹837 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyka Labs stock overvalued right now?
Based on GuruFocus' analysis, Lyka Labs (BOM:500259) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹127.51, compared to a current price of ₹63.57 — trading 50.1% below its estimated fair value. The current Total Liabilities is ₹837 Mil. Lyka Labs' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Lyka Labs (BOM:500259), the current Total Liabilities is ₹837 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyka Labs (BOM:500259) Overvalued in 2026?

Based on GuruFocus' analysis, Lyka Labs stock appears to be undervalued. The current stock price of ₹63.57 is trading 50.1% below its estimated GF Value™ of ₹127.51. GuruFocus considers Lyka Labs to be Significantly Undervalued.

Key valuation signals for BOM:500259:

  • Total Liabilities: ₹837 Mil
  • GF Value™: ₹127.51 vs. price of ₹63.57 (50.1% below fair value)
  • GF Score™: 51/100 with 2 warning signs

No single metric tells the full story. See the BOM:500259 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyka Labs Business Description

Other Exchanges LYKALABS:India
Address 30, Forjett Street, Near Bhatia Hospital, Ground floor, Spencer Building (Block B & C), Grant Road (West), Mumbai, MH, IND, 400036
Lyka Labs Ltd is an Indian biotechnology company. It mainly engages in the development of specialized formulations. The Company is engaged in only one segment which is pharmaceuticals. The Company has a presence in Domestic as well as International markets. The commercialized formulations of the company consist of hair care, anti-aging, acne management, skin lightening, face washes, sunscreens, facial scrubs, and others. It has developed a varied drug delivery system for topical steroids, painkillers, anti-fungal, and other emollients as well as liquid injectables, lyophilized injectables in the anti-bacterial, antifungal segment. The company also manufactures proton pump inhibitors, antibiotics, antifungals, steroids, etc. The majority of the company's revenue comes from India.
51GF Score

Get the complete analysis for BOM:500259

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹63.57
Price
₹127.51
GF Value